Finke et al., 2021 found a lower rate, 11.4%, of abnormally high hs-cTnT concentration assessed during or after cancer treatment in a large cohort of 930 patients treated with diverse antineoplastic regimens, with only one-fourth of them receiving anthracyclines [27]. This evidence concerns the gene TNNT2 and cancer.